Expression and functional characterization of P2Y1 and P2Y 12 nucleotide receptors in long-term serum-deprived glioma C6 cells

FEBS Journal

Volumn 274, Issue 8, 2007, Pages 1970-1982

  Krzemiński, Patryk ^a   Supłat, Dorota ^a   Czajkowski, Rafał ^a   Pomorski, Paweł ^a   Barańska, Jolanta ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Akt; Glioma C6 cells; Mitogen activated protein kinase; Nucleotide receptors; Serum deprivation

Indexed keywords

BOVINE SERUM ALBUMIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEOGLYCAN; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL ADHESION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL DIVISION; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROBLAST; GLIOMA CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, PURINERGIC P2;

BOVINAE;

EID: 34247154451     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.05741.x     Document Type: Article

References (47)

1. Brismar T (1995) Physiology of transformed glial cells. Glia 15, 231-243.
2. Grobben B, De Deyn PP & Slegers H (2002) Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310, 257-270.
3. Kubiatowski T, Jang T, Lachyankar MB, Salmonsen R, Nabi RR, Quesenberry PJ, Litofsky NS, Ross AH & Recht LD (2001) Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg 95, 480-488.
4. Vajkoczy P, Goldbrunner R, Farhadi M, Vince G, Schilling L, Tonn JC, Schmiedek P & Menger MD (1999) Glioma cell migration is associated with glioma-induced angiogenesis in vivo. Int J Dev Neurosci 17, 557-563.
5. Burnstock G, Cocks T, Kasakov L & Wong HK (1978) Direct evidence for ATP release from non-adrenergic, non-cholinergic ('purinergic') nerves in the guinea-pig taenia coli and bladder. Eur J Pharmacol 49, 145-149.
6. Abbracchio MP & Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64, 445-475.
7. Boeynaems JM, Communi D, Savi P & Herbert JM (2000) P2Y receptors: in the middle of the road. Trends Pharmacol Sci 21, 1-3.
8. Sak K & Illes P (2005) Neuronal and glial cell lines as model systems for studying P2Y receptor pharmacology. Neurochem Int 47, 401-412.
9. Boarder MR & Hourani SM (1998) The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. Trends Pharmacol Sci 19, 99-107.
10. Boyer JL, Lazarowski ER, Chen XH & Harden TK (1993) Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase. J Pharmacol Exp Ther 267, 1140-1146.
11. Grobben B, Claes P, Van Kolen K, Roymans D, Fransen P, Sys SU & Slegers H (2001) Agonists of the P2Y (AC)-receptor activate MAP kinase by a ras-independent pathway in rat C6 glioma. J Neurochem 78, 1325-1338.
12. Pianet I, Merle M & Labouesse J (1989) ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isoproterenol-stimulated C6 glioma cells. Biochem Biophys Res Commun 163, 1150-1157.
13. Schachter JB, Boyer JL, Li Q, Nicholas RA & Harden TK (1997) Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C. Br J Pharmacol 122, 1021-1024.
14. Schachter JB, Li Q, Boyer JL, Nicholas RA & Harden TK (1996) Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J Pharmacol 118, 167-173.
15. Communi D, Gonzalez NS, Detheux M, Brezillon S, Lannoy V, Parmentier M & Boeynaems JM (2001) Identification of a novel human ADP receptor coupled to G (i). J Biol Chem 276, 41479-41485.
16. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D & Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409, 202-207.
17. Savi P, Labouret C, Delesque N, Guette F, Lupker J & Herbert JM (2001) P2y (12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283, 379-383.
18. Czajkowski R, Lei L, Sabala P & Baranska J (2002) ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y (1) and P2Y (12). FEBS Lett 513, 179-183.
19. Sabala P, Czajkowski R, Przybylek K, Kalita K, Kaczmarek L & Baranska J (2001) Two subtypes of G protein-coupled nucleotide receptors, P2Y (1) and P2Y (2) are involved in calcium signalling in glioma C6 cells. Br J Pharmacol 132, 393-402.
20. Baranska J, Czajkowski R & Sabala P (2004) Cross-talks between nucleotide receptor-induced signaling pathways in serum-deprived and non-starved glioma C6 cells. Adv Enzyme Regul 44, 219-232.
21. Grobben B, Anciaux K, Roymans D, Stefan C, Bollen M, Esmans EL & Slegers H (1999) An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. J Neurochem 72, 826-834.
22. Czajkowski R, Banachewicz W, Ilnytska O, Drobot LB & Baranska J (2004) Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells. Br J Pharmacol 141, 497-507.
23. Czajkowski R & Baranska J (2002) Cross-talk between the ATP and ADP nucleotide receptor signalling pathways in glioma C6 cells. Acta Biochim Pol 49, 877-889.
24. Supłat D, Krzemiński P, Pomorski P & Barańska J (2007) P2Y1 and P2Y12 receptors cross-talk in calcium signalling: evidence from non-starved and long-term serum-deprived glioma C6 cells. Purinergic Signalling in press.
25. Hanahan D & Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57-70.
26. Chou RC & Langan TJ (2003) In vitro synchronization of mammalian astrocytic cultures by serum deprivation. Brain Res Brain Res Protoc 11, 162-167.
27. Tu MT, Luo SF, Wang CC, Chien CS, Chiu CT, Lin CC & Yang CM (2000) P2Y (2) receptor-mediated proliferation of C (6) glioma cells via activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol 129, 1481-1489.
28. Claes P, Van Kolen K, Roymans D, Blero D, Vissenberg K, Erneux C, Verbelen JP, Esmans EL & Slegers H (2004) Reactive blue 2 inhibition of cyclic AMP-dependent differentiation of rat C6 glioma cells by purinergic receptor-independent inactivation of phosphatidylinositol 3-kinase. Biochem Pharmacol 67, 1489-1498.
29. Oey J (1975) Noradrealine induces morphological alterations in nucleated and enucleated rat C6 glioma cells. Nature 257, 317-319.
30. Dahl D (1981) The vimentin-GFA protein transition in rat neuroglia cytoskeleton occurs at the time of myelination. J Neurosci Res 6, 741-748.
31. Messens J & Slegers H (1992) Synthesis of glial fibrillary acidic protein in rat C6 glioma in chemically defined medium: cyclic AMP-dependent transcriptional and translational regulation. J Neurochem 58, 2071-2080.
32. Lee K, Kentroti S, Billie H, Bruce C & Vernadakis A (1992) Comparative biochemical, morphological, and immunocytochemical studies between C-6 glial cells of early and late passages and advanced passages of glial cells derived from aged mouse cerebral hemispheres. Glia 6, 245-257.
33. Deng W & Poretz RD (2003) Oligodendroglia in developmental neurotoxicity. Neurotoxicology 24, 161-178.
34. Krzeminski P, Misiewicz I, Pomorski P, Kasprzycka-Guttman T & Baranska J (2007) Mitochondrial localization of P2Y1, P2Y2 and P2Y12 receptors in rat astrocytes and glioma C6 cells. Brain Res Bull 71, 587-592.
35. Lazarowski ER, Boucher RC & Harden TK (2000) Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem 275, 31061-31068.
36. Hardy AR, Jones ML, Mundell SJ & Poole AW (2004) Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood 104, 1745-1752.
37. Cantley LC & Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96, 4240-4245.
38. Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman DM & Gutmann DH (1999) Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem 274, 25842-25848.
39. Kim S, Jee K, Kim D, Koh H & Chung J (2001) Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J Biol Chem 276, 12864-12870.
40. Kurino M, Fukunaga K, Ushio Y & Miyamoto E (1996) Cyclic AMP inhibits activation of mitogen-activated protein kinase and cell proliferation in response to growth factors in cultured rat cortical astrocytes. J Neurochem 67, 2246-2255.
41. Qiu W, Zhuang S, von Lintig FC, Boss GR & Pilz RB (2000) Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins. J Biol Chem 275, 31921-31929.
42. Wang L, Liu F & Adamo ML (2001) Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways by inhibiting Rap1. J Biol Chem 276, 37242-37249.
43. Van Kolen K & Slegers H (2004) P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B. J Neurochem 89, 442-453.
44. Coyle DE (1995) Adaptation of C6 glioma cells to serum-free conditions leads to the expression of a mixed astrocyte-oligodendrocyte phenotype and increased production of neurite-promoting activity. J Neurosci Res 41, 374-385.
45. Prasad KN, Hovland AR, Nahreini P, Cole WC, Hovland P, Kumar B & Prasad KC (2001) Differentiation genes: are they primary targets for human carcinogenesis? Exp Biol Med (Maywood) 226, 805-813.
46. Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, Di Santo JP & Bikfalvi A (2001) Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 61, 1717-1726.
47. Machein MR, Risau W & Plate KH (1999) Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 10, 1117-1128.